High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Summary

Presented is a protocol for high-throughput drug screening to improve sleep by monitoring the sleep behavior of fruit flies in an elderly Drosophila model.

Abstract

Sleep, an essential component of health and overall well-being, often presents challenges for older individuals who frequently experience sleep disorders characterized by shortened sleep duration and fragmented patterns. These sleep disruptions also correlate with an increased risk of various illnesses in the elderly, including diabetes, cardiovascular diseases, and psychological disorders. Unfortunately, existing drugs for sleep disorders are associated with significant side effects such as cognitive impairment and addiction. Consequently, the development of new, safer, and more effective sleep disorder medications is urgently needed. However, the high cost and lengthy experimental duration of current drug screening methods remain limiting factors.

This protocol describes a cost-effective and high-throughput screening method that utilizes Drosophila melanogaster, a species with a highly conserved sleep regulation mechanism compared to mammals, making it an ideal model for studying sleep disorders in the elderly. By administering various small compounds to aged flies, we can assess their effects on sleep disorders. The sleep behaviors of these flies are recorded using an infrared monitoring device and analyzed with the open-source data package Sleep and Circadian Analysis MATLAB Program 2020 (SCAMP2020). This protocol offers a low-cost, reproducible, and efficient screening approach for sleep regulation. Fruit flies, due to their short life cycle, low husbandry cost, and ease of handling, serve as excellent subjects for this method. As an illustration, Reserpine, one of the tested drugs, demonstrated the ability to promote sleep duration in elderly flies, highlighting the effectiveness of this protocol.

Introduction

Sleep, one of the essential behaviors necessary for human survival, is characterized by two main states: rapid eye movement (REM) sleep and non-rapid eye movement (NREM) sleep¹. NREM sleep comprises three stages: N1 (the transition between wakefulness and sleep), N2 (light sleep), and N3 (deep sleep, slow wave sleep), representing the progression from wakefulness to deep sleep¹. Sleep plays a crucial role in both physical and mental health². However, aging reduces total sleep duration, sleep efficiency, slow-wave sleep percentage, and REM sleep percentage in adults³. Older individuals tend to spend more time in light sleep compared to slow-wave sleep, making them more sensitive to nocturnal awakenings. As the number of awakenings increases, average sleep time decreases, resulting in a fragmented sleep pattern in the elderly, which may be associated with excessive excitation of Hcrt neurons in mice⁴. Additionally, age-related declines in circadian mechanisms contribute to an earlier shift in sleep duration^5,6. In combination with physical illness, psychological stress, environmental factors, and medication use, these factors make older adults more susceptible to sleep disorders, such as insomnia, REM sleep behavior disorder, narcolepsy, periodic leg movements, restless legs syndrome, and sleep-disordered breathing^7,8.

Epidemiological studies have shown that sleep disorders are closely linked to chronic diseases in the elderly⁹, including depression¹⁰, cardiovascular disease¹¹, and dementia¹². Addressing sleep disorders plays a crucial role in improving and treating chronic diseases and enhancing the quality of life for older adults. Currently, patients primarily rely on drugs such as benzodiazepines, non-benzodiazepines, and melatonin receptor agonists to enhance sleep quality¹³. However, benzodiazepines can lead to downregulation of receptors and dependence after long-term use, causing severe withdrawal symptoms upon discontinuation^14,15. Non-benzodiazepine drugs also carry risks, including dementia¹⁶, fractures¹⁷, and cancer¹⁸. The commonly used melatonin receptor agonist, ramelteon, reduces sleep latency but does not increase sleep duration and has hepatic function-related concerns due to extensive first-pass elimination¹⁹. Agomelatine, a melatonin receptor agonist and serotonin receptor antagonist, improves depression-related insomnia but also poses a risk of liver damage²⁰. Consequently, there is an urgent need for safer drugs to treat or alleviate sleep disorders. However, current drug screening strategies, based on molecular and cellular experiments combined with automated systems and computer analysis, are expensive and time-consuming²¹. Structure-based drug design strategies, relying on receptor structure and properties, require a clear understanding of receptor three-dimensional structure and lack predictive capabilities for drug effects²².

In 2000, based on the sleep criteria proposed by Campbell and Tobler in 1984²³, researchers established simple animal models to study sleep²⁴, including Drosophila melanogaster, which exhibited sleep-like states^25,26. Despite anatomical differences between Drosophila and humans, many neurochemical components and signaling pathways regulating sleep in Drosophila are conserved in mammalian sleep, facilitating the study of human neurological diseases^27,28. Drosophila is also extensively used in circadian rhythm studies, despite differences in core oscillators between flies and mammals^29,30,31. Therefore, Drosophila serves as a valuable model organism for studying sleep behavior and conducting sleep-related drug screening.

This study proposes a cost-effective and simple phenotype-based approach for screening small-molecule drugs to treat sleep disorders using aged flies. Sleep regulation in Drosophila is highly conserved²⁵, and the decline in sleep observed with age may be reversible through drug administration. Thus, this sleep phenotype-based screening method can intuitively reflect drug efficacy. We feed the flies with a mixture of the drug under investigation and food, monitor and record sleep behavior using the Drosophila Activity Monitor (DAM)³², and analyze the acquired data using the open-source SCAMP2020 data package in MATLAB (Figure1). Statistical analysis is performed using statistics and graphing software (see Table of Materials). As an example, we demonstrate the effectiveness of this protocol by presenting experimental data on Reserpine, a small-molecule inhibitor of the vesicular monoamine transporter reported to increase sleep³³. This protocol provides a valuable approach to identify drugs for treating age-related sleep problems.

Protocol

This protocol uses the 30-day-old w¹¹¹⁸ flies from the Bloomington Drosophila Stock Center (BDSC_3605, see Table of Materials).

1. Preparation of the aged fruit flies

1. Food preparation
   1. Prepare standard corn starch culture medium by mixing 50 g/L cornflakes, 110 g/L sugar, 5 g/L agar, and 25 g/L yeast. Heat the cornflakes and yeast with water to gelatinize, and then fully dissolve all the substances.
   2. When the medium cools to 50-60 °C, add 6 mL/L of propionic acid and promptly pack them into culture bottles.
2. Fly rearing and preparation of aged flies
   1. Breed the fly strain w¹¹¹⁸ in bottles containing a standard cornstarch culture medium and put bottles in a constant temperature incubator at 25° C, 68% relative humidity, 500-1000 lux lighting conditions, and a 12 h:12 h light: dark cycle.
   2. Transfer flies into a new bottle every 7 days according to the growth cycle of flies, keeping the age of individuals in the same bottle consistent.
   3. Collect the new batch of flies that hatch from the original bottle 3 days after transferring them and put them into a new bottle. Following the principle of changing the bottle every 7 days, they will be cultured until around 30 days old.

2. Preparation of medicinal food and glass tubes for monitoring

NOTE: The procedure for glass tube preparation follows the work of Jin et al. with modifications³⁴.

1. Cleaning and drying of glass tubes
   1. Place the glass tube (5 mm in diameter x 65 mm in length, see Table of Materials) into a large beaker, soak it, and boil it with double distilled water for 20 min. Repeat 3 times.
   2. Remove and bundle the glass tube, rinse the inside with double distilled water 3-5 times, and place it in an oven for drying.
2. Preparation of simple culture medium (100 mL)
   1. Dissolve 1.5 g agar and 5 g sucrose in double distilled water, heat, and concentrate to 100 mL.
   2. Add 600 µL propionic acid when the medium cools to about 70 °C, preventing it from solidifying using a constant temperature water bath.
   3. Add approximately 4 mL of simple medium and Reserpine (see Table of Materials) into a 10 mL small beaker until the drug reaches 20 µM or 50 µM. Add dimethyl sulfoxide (DMSO) to the concentration of 0.2% in the negative control group.
3. Preparation of the glass tubes containing medicine
   1. To facilitate the flow of the medium, carefully insert a suitable length of glass tube into a small beaker. The medium will naturally enter the glass tube due to atmospheric pressure.
   2. Pull out the glass tube when the culture medium is completely solidified and wipe the outer wall to obtain a monitoring glass tube with a culture medium containing drugs at one end.
   3. Heat the solid paraffin in a beaker until it melts at 70 °C, put the end of the glass tube close to the food into the paraffin liquid for about 5 mm, and quickly remove it. Wait for the paraffin to solidify to seal the food end of the glass tube.

3. Experimental design and fly treatment

1. Design the experiment for the fly treatment following Table 1.

4. Drosophila assembly and sleep monitoring

NOTE: The procedure for Drosophila assembly follows the work of Jin et al.³⁴ with modifications.

1. Anesthetize flies with CO₂ gas, put them into paraffin-sealed glass tubes (one per tube), and block the non-food end with an absorbent cotton ball to prevent flies from escaping and ensure air circulation.
2. Load tubes onto the infrared monitor for monitoring them.
   1. Assemble the glass tubes containing flies onto an infrared monitor in the same direction, and record the monitor number and hole number corresponding to each drug.
   2. Adjust the alignment of each tube, and make the infrared rays pass vertically through the center of the fly's activity range.
   3. Place the monitor inside a 25 °C incubator located in the fly sleep darkroom, following the specified settings: 25 °C temperature, Zeitgeber 12 (ZT12) (equivalent to local time 08:00 p.m.), and ZT24 (equivalent to local time 08:00 a.m.). This setup ensures that the flies experience alternating periods of 12 h of light and darkness.
      NOTE: Try not to open the door until monitoring data collection is complete to maintain a stable environment in the incubator during monitoring.
   4. Start monitoring using the DAM2 system (see Table of Materials).
   5. Once the monitoring is complete, download the collected data in .txt format from the system.

5. Data processing

NOTE: The data processing using the DAM system, DAMFileScan107, and SCAMP was performed according to the instructions on their official websites (see Table of Materials).

1. Import the above txt file into DAMFileScan107 software for scanning and divide it as needed to obtain sleep data.
   1. Set the starting time of segmentation data to 8:01 (1 min segmentation) or 8:00 (30 min segmentation) on the third morning after starting the monitors, and the termination time is 8:00 a.m. three days after the starting time (Figure 2A1).
      NOTE: Flies must adapt to the monitoring environment for at least one day. So, one can set the split data start time to 8 a.m. on the third day after the monitor begins.
   2. Split the data at intervals of 1 min and 30 min. Change the option "Bin Length" to 1 minute, change the option "Output File Type" to Channel files, rename, and output. The 30 min data segmentation method is the same as above (Figure 2A2-5).
      NOTE: When performing data segmentation at 1 min and 30 min intervals, the final renaming of the two files should be consistent; otherwise, it may be unreadable during subsequent Matlab processing. If necessary, the file name can be changed after output to facilitate differentiation.
2. Data processing using SCAMP2020
   1. Open the program package SCAMP2020 in Matlab, and double-click on Vecsey Sleep and Circadian Analysis MATLAB Program (SCAMP) (Figure 2B).
   2. Add its subfolder "Vecsey SCAMP Scripts" to the path, find the file "scamp.m" in that folder, and run it. In the following pop-up window, select the process 1 min and 30 min folders in sequence (Figure 2C,D).
   3. Select a monitor, click on Load individual See Plots to preview (Figure 3A1), and check the image that appears. Uncheck the corresponding channel of dead flies (Figure 3A2, Figure 3B).
   4. Repeat the above steps to check all monitors.
   5. Rename each channel in each monitor based on the corresponding drug to be tested (Figure 3A3), select all monitors, and click on ANALYZE Selected Data for analysis (Figure 3A4).
   6. Default to the selected option, click on Analyze for Chosen Bin, check Export Data, and finally click on GRAPH 30 min Data Types for All Days for Selected Groups and EXPORT All Data to output the results (Figure 3C).
3. Select the file named s30 from the CSV file, find the corresponding mean value and standard error data for each monitor, back up it to Excel for modification and adjustment, and paste it into GraphPad Prism (see Table of Materials) to draw a sleep status diagram (Figure 4A,B).
4. Find the file named "stdur" and calculate the average values of daytime, nighttime, and total sleep for each fly within three days (Figure 4A,C). Paste the data into the Prism software to complete the difference test and draw a graph.

Results

Reserpine is a small-molecule inhibitor of the vesicular monoamine transporter (VMAT), which inhibits the reuptake of monoamines into presynaptic vesicles, leading to increased sleep³³. The sleep-promoting effects of Reserpine were examined in 30-day-old flies, with the control group being fed solely with the solvent dimethyl sulfoxide (DMSO). In the Reserpine group, older flies exhibited significantly increased sleep during both the day and night compared to the DMSO group. F...

Discussion

The described method is suitable for rapidly screening small and medium-sized sleep drugs. Currently, most mainstream high-throughput drug screening methods are based on biochemical and cellular levels. For example, the structure and properties of the receptor are examined to search for specific ligands that can bind to it²². Another approach involves analyzing the binding mode and strength of molecular fragments of selected drugs using Nuclear Magnetic Resonance (NMR) with mass spectrometry

Materials

Name	Company	Catalog Number	Comments
Ager	BIOFROXX	8211KG001
Artificial Climate Box	PRANDT	PRX-1000A	official website:https://www.nbplt17.com/PLTXBS-Products-20643427/
DAM2 Drosophila Activity Monitor	TriKineics	DAM2	official website:https://www.trikinetics.com/
DAM2system	TriKineics	version:v3.03	official website:https://www.trikinetics.com/
DAMFileScan	TriKineics	version:1.0.7.0	official website:https://www.trikinetics.com/
Dimethyl Sulfoxide	SIGMA	276855
Drosophila Activity Monitoring Incubator	Tritech Research	DT2-CIRC-TK	official website:https://www.tritechresearch.com/DT2-CIRC-TK.html
Drosophila Bottles	Biologix	51-17720	official website:http://biologixgroup.com/goods.php?id=48
Drosophila: w1118	Bloomington Drosophila Stock Center	BDSC_3605
Excel	Microsoft	version:Excel 2016	official website:https://www.microsoftstore.com.cn/software/office/excel
Glass tubes	TriKinetics	PPT5x65	official website:https://www.trikinetics.com/
MATLABR2022b	MathWorks	version:9.13.0.2049777	official website:https://ww2.mathworks.cn/products/matlab.html
Prism	GraphPad	Version:Prism 8.0.1	official website:https://www.graphpad.com/features
Reserpine	MACKLIN	R817202-1g
Saccharose	SIGMA	1245GR500
SCAMP	Vecsey Lab	N/A	official website:https://academics.skidmore.edu/blogs/cvecsey/